PE20121171A1 - Metodo, kit, plasmido y composicion para inducir una respuesta inmunitaria contra el virus del dengue basandose en vacunas de adn y virus quimericos - Google Patents

Metodo, kit, plasmido y composicion para inducir una respuesta inmunitaria contra el virus del dengue basandose en vacunas de adn y virus quimericos

Info

Publication number
PE20121171A1
PE20121171A1 PE2012000411A PE2012000411A PE20121171A1 PE 20121171 A1 PE20121171 A1 PE 20121171A1 PE 2012000411 A PE2012000411 A PE 2012000411A PE 2012000411 A PE2012000411 A PE 2012000411A PE 20121171 A1 PE20121171 A1 PE 20121171A1
Authority
PE
Peru
Prior art keywords
dengue virus
viruses
composition
dna vaccines
chemeric
Prior art date
Application number
PE2012000411A
Other languages
English (en)
Inventor
Ada Maria De Barcelos Alves
Adriana De Souza Azevedo
Ricardo Galler
Marcos Da Silva Freire
Original Assignee
Fundação Oswaldo Cruz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43825448&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20121171(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fundação Oswaldo Cruz filed Critical Fundação Oswaldo Cruz
Publication of PE20121171A1 publication Critical patent/PE20121171A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

REFERIDA A UNA COMPOSICION DE VACUNA CONTRA EL VIRUS DEL DENGUE QUE COMPRENDE: a) VACUNAS DE ADN CONTRA LOS CUATRO SEROTIPOS DEL VIRUS DEL DENGUE A PARTIR DE LA CONSTRUCCION DE DIFERENTES PLASMIDOS RECOMBINANTES QUE CONTIENEN LOS GENES QUE CODIFICAN PARA LAS PROTEINAS E DE CADA SEROTIPO DEL VIRUS DEL DENGUE, O SOLO LAS SECUENCIAS CORRESPONDIENTES A LOS DOMINIOS III DE ESTAS PROTEINAS, TODAS FUSIONADAS A LA SECUENCIA QUE CODIFICA PARA EL PEPTIDO SENAL DEL ACTIVADOR DEL PLASMINOGENO TISULAR HUMANO (t-PA), b) VIRUS QUIMERICOS QUE COMPRENDEN EL VIRUS DE LA VACUNA DE LA FIEBRE AMARILLA 17D MODIFICADO, CON LA SUSTITUCION DE LAS SECUENCIAS QUE CODIFICAN PARA LAS PROTEINAS prM Y E DE LA FEBRE AMARILLA POR SECUENCIAS QUE CODIFICAN PARA LAS PROTEINAS prM Y E DEL VIRUS DEL DENGUE DE DIFERENTES SEROTIPOS Y c) UN VEHICULO FARMACEUTICAMENTE ACEPTABLE
PE2012000411A 2009-10-01 2010-08-01 Metodo, kit, plasmido y composicion para inducir una respuesta inmunitaria contra el virus del dengue basandose en vacunas de adn y virus quimericos PE20121171A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRPI0904020A BRPI0904020B8 (pt) 2009-10-01 2009-10-01 composição vacinal contra o vírus da dengue, e, kit

Publications (1)

Publication Number Publication Date
PE20121171A1 true PE20121171A1 (es) 2012-08-30

Family

ID=43825448

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2016001214A PE20161094A1 (es) 2009-10-01 2010-08-01 Metodo, kit, plasmido y composicion para inducir una respuesta inmunitaria contra el virus del dengue basandose en vacunas de adn y virus quimericos
PE2012000411A PE20121171A1 (es) 2009-10-01 2010-08-01 Metodo, kit, plasmido y composicion para inducir una respuesta inmunitaria contra el virus del dengue basandose en vacunas de adn y virus quimericos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2016001214A PE20161094A1 (es) 2009-10-01 2010-08-01 Metodo, kit, plasmido y composicion para inducir una respuesta inmunitaria contra el virus del dengue basandose en vacunas de adn y virus quimericos

Country Status (10)

Country Link
US (1) US10357558B2 (es)
EP (1) EP2484376A4 (es)
CN (1) CN102711817B (es)
BR (1) BRPI0904020B8 (es)
CL (1) CL2012000783A1 (es)
CO (1) CO6541529A2 (es)
CU (1) CU24060B1 (es)
EC (1) ECSP12012131A (es)
PE (2) PE20161094A1 (es)
WO (1) WO2011038473A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3177574A1 (en) * 2013-03-15 2014-09-25 Takeda Vaccines, Inc. Compositions and methods for dengue virus chimeric constructs in vaccines
MX366154B (es) 2013-06-21 2019-06-28 Merck Sharp & Dohme Composiciones de vacuna del virus del dengue y metodos de uso de las mismas.
ITRM20130458A1 (it) 2013-08-05 2015-02-05 Internat Ct For Genetic En Gineering And Vaccino genetico anti-dengue virus basato sugli ectodomini della proteina envelope
EP3236997B1 (en) * 2014-12-22 2024-05-29 Merck Sharp & Dohme LLC Dengue virus vaccine compositions and methods of use thereof
US20220226401A1 (en) 2018-09-05 2022-07-21 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455509B1 (en) * 1996-06-04 2002-09-24 The United States Of America As Represented By The Secretary Of The Navy Dengue nucleic acid vaccines that induce neutralizing antibodies
US6962708B1 (en) * 1997-02-28 2005-11-08 Acambis, Inc. Chimeric flavivirus vaccines
BRPI9701774B8 (pt) 1997-04-11 2015-09-29 Fundação Oswaldo Cruz Fiocruz cdna mutante e infeccioso do vírus da febre amarela, constructo de dna, vírus recombinante de febre amarela e vacina para humanos contra infecções de febre amarela.
US6881723B1 (en) * 1998-11-05 2005-04-19 Powderject Vaccines, Inc. Nucleic acid constructs
WO2003102166A2 (en) * 2002-02-26 2003-12-11 Maxygen, Inc. Novel flavivirus antigens
CA2618783A1 (en) 2005-08-10 2007-02-22 Acambis Inc. Vaccination against dengue virus infection
CN101287490B (zh) * 2005-08-10 2013-04-24 阿坎姆比斯公司 对抗登革热病毒感染的疫苗接种
CU23586A1 (es) * 2005-11-22 2010-10-30 Ct Ingenieria Genetica Biotech Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
EP2462930B1 (en) * 2006-11-09 2017-05-31 The United States Of America As Represented By The Secretary Of The Navy Induction of an immune response against dengue virus using prime-boost approach
KR101686942B1 (ko) * 2008-01-11 2016-12-28 이노비오 파마수티컬즈, 인크. 뎅기 바이러스 다중 서브타입에 대항하는 신규한 백신

Also Published As

Publication number Publication date
CU24060B1 (es) 2014-12-26
WO2011038473A8 (pt) 2012-07-19
BRPI0904020A2 (pt) 2011-06-14
CL2012000783A1 (es) 2013-03-22
WO2011038473A1 (pt) 2011-04-07
CN102711817A (zh) 2012-10-03
CO6541529A2 (es) 2012-10-16
ECSP12012131A (es) 2013-02-28
EP2484376A4 (en) 2014-01-22
EP2484376A1 (en) 2012-08-08
PE20161094A1 (es) 2016-10-22
CU20120057A7 (es) 2013-01-30
CN102711817B (zh) 2016-10-26
BRPI0904020B8 (pt) 2021-05-25
US20120251570A1 (en) 2012-10-04
US10357558B2 (en) 2019-07-23
BRPI0904020B1 (pt) 2019-11-12

Similar Documents

Publication Publication Date Title
PE20121171A1 (es) Metodo, kit, plasmido y composicion para inducir una respuesta inmunitaria contra el virus del dengue basandose en vacunas de adn y virus quimericos
EA202192570A1 (ru) Иммуногенные композиции и вакцины, содержащие пептиды и белки вируса африканской чумы свиней, и их применение
CO2020004738A2 (es) Variantes de cápsides de virus adenoasociados y métodos de uso de estas
BRPI0913012A2 (pt) vírus do nilo ocidental/da dengue quiméricos
ES2662801T3 (es) Vacunas atenuadas contra Streptoccocus suis y procedimientos de fabricación y uso de las mismas
NO20090194L (no) Rekombinant viral vaksine
JP2009544333A5 (es)
ATE533782T1 (de) Impfstoffe und immuntherapeutika mit codon- optimiertem il-15 und verwendungsverfahren dafür
AR061484A1 (es) Secuencias de adn vectores proteinas y usos de hemaglutinina de gripe aviar
AR087020A1 (es) Polipeptidos de fusion de relaxina y usos de los mismos
PE20160188A1 (es) Variantes aav y composiciones, metodos y usos para transferencia de gen a celulas, organos y tejidos
AR086078A1 (es) Proteinas de fusion y vacunas de combinacion
EA202092990A3 (ru) Молекула нуклеиновой кислоты, кодирующая коровый белок вируса гепатита в, и вакцина, содержащая указанную молекулу
NO20090780L (no) Human Glp-1 mimetistoff, sammensetninger, fremgangsmater og anvendelser
WO2009124312A3 (en) Consensus sequences of chikungunya viral proteins, nucleic acid molecules encoding the same, and compositions and methods for using the same
CL2012000447A1 (es) Composición o vacuna que comprende un vector viral de un paramixovirus aviar 8 (apmv-8) recombinante; método para producir dicho vector; y uso para preparar medicamento útil para inducir una respuesta inmunológica.
Li et al. Recovery of a chemically synthesized Japanese encephalitis virus reveals two critical adaptive mutations in NS2B and NS4A
BR112015005987A2 (pt) vacina, métodos para induzir uma resposta imune contra um antígeno hbv, para proteção de um sujeito da infeção por hbv, para proteger o sujeito que foi diagnosticado com uma infecção por hbv, para induzir uma resposta imune contra um antígeno do hbv, para proteger um indivíduo da infecção pelo hbv, para proteger um indivíduo que foi diagnosticado com infecção pelo hbv, para proteger um indivíduo da infecção pelo hbv, para proteger um indivíduo que foi diagnosticado com infecção pelo hbv, para proteger um sujeito contra infecção por hbv e para proteger o sujeito que foi diagnosticado com uma infecção por hbv, molécula de ácido nucleico, e, proteína
UA108902C2 (uk) Вірус північноамериканського репродуктивного та респіраторного синдрому свиней (prrs) та його застосування
AR080313A1 (es) Composiciones de virus de moquillo canino (cdv) recombinante y sus usos
EA201990717A1 (ru) Новая вакцина против гриппа свиней
AR094725A1 (es) Parvovirus 5a porcino, métodos de uso y vacuna
Lazo et al. Aiming at the heart: the capsid protein of dengue virus as a vaccine candidate
EA200601043A1 (ru) Промоторы для экспрессии в модифицированном вирусе осповакцины штамма анкара
MX2017014417A (es) Vacunas contra el dengue.

Legal Events

Date Code Title Description
FG Grant, registration